A recent conference entitled “Safe and Secure Biomaterials: Matching Resources to Reality”, on Thursday 17 May 2012 at the Chatham House (UK) presented researchers with a disturbing report regarding the lack of biosafety controls that were found in “developing countries”. …

Osiris Therapeutics’s drug  Prochymal (remestemcel-L), for acute graft-versus host disease (GvHD), has been approved for marketing  by regulators in Canada.  The “drug” is approved for suppressing the immune system in patients that have received transplants, where the grafts attack the patients bodies. …

From OLAW: Join us for a webinar: “Grants Policy and Congruence” on June 7, 2012 at 1:00 PM ET. Dr. Patricia Brown, OLAW Director, will discuss the requirements for assuring congruence between grant applications and what the IACUC has approved…

Beginning today, May 25th, the NIH Division of Receipt and Referral – the folks who actually receive and administratively review most applications at NIH – correspondence will be handled via a new “Correspondence” section of the detailed status screen for…

This note from Grants.gov’s blog… The General Services Administration (GSA) is moving the implementation date of the System for Award Management (SAM) from May 29, 2012 to the end of July 2012. The additional sixty days will allow federal agencies…

SAM – the System for Award Management – is a new US Governments new website scheduled to go live on May 29th at Sam.gov. If you are a research administrator, you should care. Going online in phases, SAM will consolidate…